-
Media Release
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
-
Media Release
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
-
Media Release
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
-
Media Release
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
-
Media Release
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
-
Media Release
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
-
Media Release
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
-
Media Release
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
-
Media Release
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-
Media Release
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-
Media Release
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
-
Media Release
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)